(Q37257126)

19 August 2017

1 reference

title

Bone-marrow relapse in paediatric acute lymphoblastic leukaemia (English)

1 reference

19 August 2017

1 reference

L Charles Bailey

1

1 reference

19 August 2017

Beverly J Lange

series ordinal

2

1 reference

19 August 2017

Susan R Rheingold

series ordinal

3

1 reference

19 August 2017

Nancy J Bunin

series ordinal

4

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Lancet Oncology Commission

19 August 2017

published in

1 reference

19 August 2017

volume

9

1 reference

19 August 2017

issue

9

1 reference

19 August 2017

page(s)

873-883

1 reference

Treatment of acute lymphoblastic leukemia

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Outcome after first relapse in children with acute lymphoblastic leukemia: A population‐based study of 315 patients from the nordic society of pediatric hematology and oncology (NOPHO)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

New therapeutic strategies for the treatment of acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

End points to establish the efficacy of new agents in the treatment of acute leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Shortening the timeline of pediatric phase I trials: the rolling six design

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of secon

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Expression of late cell cycle genes and an increased proliferative capacity characterize very early relapse of childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Childhood acute lymphoblastic leukaemia and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Comm

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia: a population-based case control study from the Nordic countries

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Salvage therapy for refractory or relapsed acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Cord blood transplantation for children with acute leukaemia: a Eurocord registry analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Mar

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Residual leukaemia after bone marrow transplant in children with acute lymphoblastic leukaemia after first haematological relapse or with poor initial presenting features.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Allogeneic bone marrow transplantation for childhood relapsed acute lymphoblastic leukemia: comparison of outcome in patients with and without a matched family donor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Pediatric phase I trials in oncology: an analysis of study conduct efficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Philadelphia positive acute lymphoblastic leukaemia of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Phase II window studies: 10 years of experience and counting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970229-8

7 January 2021

10.1016/S1470-2045(08)70229-8

Identifiers

DOI

1 reference

19 August 2017

1 reference